Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with 213Bi-conjugates

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 3, 2004, Pages 896-908

  Li, Yong ^a   Abbas Rizvi, Syed M ^a,b   Blair, Julie M ^b,c   Cozzi, Paul J ^b   Qu, Chang F ^a,b   Ow, Kim T ^b,c   Tam, Patrick N ^b,c   Perkins, Alan C ^d   Russell, Pamela J ^b,c   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Conjugates; Particle emitter; 213Bi; Monoclonal antibodies; Plasminogen activator inhibitor type 2; Urokinase plasminogen activator

Indexed keywords

ANTIBODIES; ANTIGENS; DISEASE CONTROL; PATIENT MONITORING; TUMORS;

ANTIGENIC EXPRESSION; CANCER CELLS; CELL LINES;

CELLS;

BISMUTH 213; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BLCA 38; MONOCLONAL ANTIBODY C595; MONOCLONAL ANTIBODY J591; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; RADIOISOTOPE; TETRAZOLIUM; UNCLASSIFIED DRUG; UROKINASE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL LABELING; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; APOPTOSIS; BISMUTH; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOCONJUGATES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 2942542582     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.04.035     Document Type: Article

References (67)

1. Greenlee R., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33
2. Denis L., Churner De Mora J.L., Bono A., et al. Goserelin acetate and flutamide versus bilateral orchiectomy A Phase III EORTC trial (30853). Urology. 42:1993;119-130
3. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424
4. Lepor H., Ross A., Walsh P.C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol. 128:1982;335-340
5. Tu S.M., Mengistu B., Delpassand E.S., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate A randomized phase II trial. Lancet. 357:2001;326-327
6. Soerdjbalie-Maikoe V., Pelger R.C.M., Lycklama a Nijeholt G.A.B., et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med. 29:2002;494-498
7. Price M.R., Pugh J.A., Hudecz F., et al. C595 - A monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer. 61:1990;681-686
8. Gendler S., Taylor-Papadimitriou J., Duhig T., et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 263:1998;12820-12823
9. Brockhausen I., Yang J., Burchell J., et al. Mechanisms underlying aberrant glycosylation of MUC1 in breast cancer cells. Eur J Biochem. 233:1995;607-617
10. Walker K.Z., Russell P.J., Kingsley E.A., et al. Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol. 142:1989;1578-1583
11. Russell PJ, Ow K, Tam PN, et al. Immunohistochemical characterization of a new monoclonal antibody, BLCA-38, for the detection of prostate cancer. Cancer Immunol Immunother 2004; in press
12. 153Samarium-labeled monoclonal antibody, BLCA-38. Antibody Immunocojugat Radiopharm 1991;4319-4330
13. Liu H., Moy P., Kim S., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57:1997;3629-3634
14. Israeli R.S., Powell C.T., Corr J.G., et al. Expression of the prostate-specific membrane antigen. Cancer Res. 54:1994;1807-1811
15. Wright G.L. Jr, Grob B.M., Haley C., et al. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 48:1996;326-334
16. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 3:1997;81-85
17. Achbarou A., Kaiser S., Tremblay G., et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:1994;2372-2377
18. Rabbani S.A., Harakidas P., Davidson D.J., et al. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer. 63:1995;840-845
19. Pollanen J., Stephens R., Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 57:1991;273-328
20. Schmitt M., Janicke F., Chucholowski N., et al. Tumour-associated urokinase-type plasminogen activator Biological and clinical significance. Biol Chem Hoppe-Seyler. 373:1992;611-622
21. Yamamoto M, Sawaya R, Mohanam S. Activities, localization and roles of serine proteases and their inhibitors in human brain tumour progression. J Neurol Oncol 1994;22139-22151
22. Mustojoki S., Alitalo R., Stephens R.W., et al. Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS. 107:1999;144-149
23. Pollanen J., Vaheri A., Tapiovaara H., et al. Urourokinase activation on the surface of human rhabdomyosarcoma cells Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA. 87:1990;2230-2234
24. Kruithof E.K., Baker M.S., Bunn C.L. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 86:1995;4007-4024
25. Rizvi S.M.A., Sarkar S., Goozee G., et al. Radioimmunoconjugates for targeted α therapy of malignant melanoma. Melanoma Res. 10:2000;281-290
26. Allen B.J., Rizvi S.M.A., Tian Z. Preclinical targeted α therapy for melanoma. Melanoma Res. 11:2001;1-8
27. Rizvi S.M.A., Henniker A.J., Goozee G., et al. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with α and beta emitting radioisotopes. Leuk Res. 26:2002;37-43
28. 213Bi)-labeled- plasminogen activator inhibitor type 2 (α-PAI2). Breast Cancer Res Treat. 71:2002;149-159
29. 213Bi-labeled-plasminogen activator inhibitor type 2. Br J Cancer. 88:2003;944-950
30. Li Y., Tian Z., Rizvi S.M.A., et al. In vitro and preclinical targeted α therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostat Dis. 5:2002;36-46
31. 213Bi-PAI2 conjugate selectively induces apoptosis in PC-3 metastatic cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer. 86:2002;1197-1230
32. 213Bi. Radiochim Acta. 79:1997;145-149
33. 213Bi for α-particle-mediated radioimmunotherapy. J Label Compds Radiopharm. 40:1997;341
34. Kaighn M.E., Shankar Narayan K., Ohnuki Y., et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:1979;16-23
35. Stone K.R., Mickey D.D., Wunderli H., et al. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1:1979;274-281
36. Pettaway C.A., Pathak S., Greene G., et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 2:1996;1627-1636
37. Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818
38. McDevitt M.R., Finn R.D., Sgouros G., et al. An 225Ac/213Bi generator system for therapeutic clinical applications Construction and operation. Appl Radiat Isotopes. 50:1999;895-904
39. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501
40. 213Bi-Herceptin α conjugate. Cancer Lett 2004;205:161-171
41. Scheinberg D.A., Strand M., Gansow O.A. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science (Washington DC). 215:1982;1511-1513
42. Vaughan A.T.M., Bateman W.J., Fisher D.R. The in vivo fate of a At-211 labeled monoclonal antibody with a known specificity in a murine system. Int J Radiat Oncol Biol Phys. 8:1982;1943-1946
43. Allen B.J. Can α-immunotherapy succeed where other systemic modalities have failed? Nucl Med Commun. 20:1999;205-207
44. 213Bi. Br J Cancer. 80:1999;175-184
45. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60:2000;6059-6100
46. Hoosein N.M., Boyd D.D., Hollas W.J., et al. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 3:1991;255-264
47. Crowley C.W., Cohen R.L., Lucas B., et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Aci USA. 90:1993;5021-5025
48. Festuccia C., Dolo V., Guerra F., et al. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis. 16:1998;513-528
49. Gaylis F.D., Keer N.H., Wilson M.J., et al. Plasminogen activators in human prostate cancer cell lines and tumors correlation with the aggressive phenotype. J Urol. 142:1989;193-198
50. Van Veldhuizen P.J., Sadasivan R., Cherian R., et al. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci. 312:1996;8-11
51. Kirchheimer J.C., Pfluger H., Ritschl P., et al. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invas Metast. 5:1985;344-355
52. Liu H., Rajasekaran A.K., Moy P., et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58:1998;4055-4060
53. Zhang S., Zhang H.S., Reuter V.E., et al. Expression of potential targeted antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 4:1998;295-302
54. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57:1997;2314-2321
55. Lapidus R.G., Tiffany C.W., Isaacs J.T., et al. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 45:2000;350-354
56. Hughes O.D.M., Denley H., Kunkler R.B., et al. MUC1 mucin expression in transitional cell carcinoma of the bladder. J Urol Pathol. 12:2000;179-191
57. Kirschenbaum A., Itzkowitz S.H., Wang J.P., et al. MUC1 expression in prostate carcinoma Correlation with grade and stage. Mol Urol. 3:1999;163-168
58. Paoadopoulos I., Sivridis E., Giatromanolaki A., et al. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res. 7:2001;1533-1538
59. Ng Y.K., Pickens C.I., Dang S.M., et al. Prognostic significance of increased immunodetectable MUC1 in prostate cancer. [Abstract] Proc Am Assoc Cancer Res. 88:1997;542
60. Agus D.B., Scher H.I., Higgins B., et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59:1999;4716-4764
61. Karashima T., Sweeney P., Slaton J.W., et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growth orthotopically in nude mice. Clin Cancer Res. 8:2002;1253-1264
62. Saffran D.C., Raitano A.B., Hubert R.S., et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 98:2002;2658-2663
63. Meredith R.F., Bueschen A.J., Khazaeli M.B., et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 35:1994;1017-1022
64. 131I-labeled CC49 Outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res. 4:1998;643-651
65. Palapattu G.S., Reiter R.E. Monoclonal antibody therapy for genitourinary oncology Promise for the future. J Urol. 168:2002;2615-2623
66. Chang C.H., Sharkey R.M., Rossi E.A., et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther. 1:2002;553-563
67. Macklis R.M., Lin J.Y., Beresford B., et al. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy Induction of apoptosis. Radiat Res. 130:1992;220-226